American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Feb 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial.
In the WILLOW trial, the Dipeptidyl peptidase-1 inhibitor brensocatib reduced neutrophil serine protease (NSP) activity and prolonged time to first exacerbation in patients with bronchiectasis. ⋯ gov, ID: NCT03218917.
-
Am. J. Respir. Crit. Care Med. · Feb 2025
Contribution of Post-TB Sequelae to Life-Years Lost from TB Disease in the United States, 2015-2019.
Individuals surviving TB disease may experience chronic sequelae that reduce survival and quality-of-life. These post-TB sequalae are not generally considered in estimates of the health impact of TB disease. ⋯ In the United States, a substantial fraction of the life-years and QALYs lost from TB are attributable to post-TB sequelae. Evidence is needed on approaches to prevent and repair post-TB lung damage, in the context of frequent co-prevalent health conditions.
-
Am. J. Respir. Crit. Care Med. · Feb 2025
Lung Cancer Screening and Incidental Findings: A Research Agenda. An Official American Thoracic Society Research Statement.
Lung cancer screening with low-dose computed tomography (LDCT) may uncover incidental findings (IFs) unrelated to lung cancer. There may be potential benefits from identifying clinically significant IFs that warrant intervention and potential harms related to identifying IFs that are not clinically significant but may result in additional evaluation, clinician effort, patient anxiety, complications, and excess cost. ⋯ This statement provides a prioritized research agenda to further efforts focused on evaluating, managing, and increasing awareness of IFs in lung cancer screening.